QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING
The present disclosure provides methods for assessing and optimizing cellular quality of a cell-based therapy that is being produced in an automated cell engineering system. The methods suitably include monitoring molecular characteristics of the cells before, during, and after the automated process to provide feedback to the process parameters. In embodiments, the cells being produced are Chimeric Antigen Receptor (CAR) T-cells.
1 . A method for assessing and optimizing cellular quality of a chimeric antigen receptor T (CAR T) cell culture, comprising:
(a) determining one or more molecular characteristics of a pre-modified T-cell culture;
(b) optimizing one or more parameters of an automated cell engineering system to alter the one or more molecular characteristics of the pre-modified T-cell culture;
(c) activating the pre-modified T-cell culture with an activation reagent to produce an activated T-cell culture;
(d) genetically modifying the activated T-cell culture to encode an ectodomain, a transmembrane domain, and an endodomain of a chimeric antigen receptor (CAR), to produce a CAR T-cell culture;
(e) expanding the CAR T-cell culture;
(f) concentrating the expanded CAR T-cell culture of (e);
(g) harvesting the concentrated CAR-T cell culture of (f);
(h) automatically determining via the automated cell engineering system the one or more molecular characteristics of the CAR T-cell culture during or after any one of steps (c)-(g); and
(i) automatically optimizing one or more parameters of any one of steps (c)-(g) to alter the one or more molecular characteristics of the CAR T-cell culture based on the automatically determined one or more molecular characteristics, wherein the optimizing includes one or more of increasing or decreasing a flow rate of cell media, increasing or decreasing oxygen concentration, increasing or decreasing carbon dioxide concentration, increasing or decreasing a glucose level, increasing or decreasing a pH of cell media, and/or modifying a selection reagent used in a cell isolation procedure.
2 . The method of claim 1 , wherein the method produces about 100 million viable CAR T-cells.
3 . The method of claim 1 , wherein the T-cell culture comprises at least one accessory cell, peripheral blood mononuclear cells and/or purified T-cells.
4 . The method of claim 3 , wherein the accessory cell comprises a monocyte or a monocyte-derived cell and antigens for a T-cell receptor comprising CD28, CD40, CD2, CD40L and/or ICOS.
5 . The method of claim 1 , wherein the activation reagent comprises an antibody or a dendritic cell.
6 . The method of claim 5 , wherein the antibody is a soluble antibody, comprises at least one of an anti-CD3 antibody and an anti-CD28 antibody and/or is immobilized on a surface.
7 . The method of claim 6 , wherein the surface is a surface of a bead.
8 . The method of claim 1 , wherein the genetically modifying comprises one of transduction, viral infection, electroporation, membrane disruption, or combinations thereof.
9 . The method of claim 8 , wherein the genetically modifying comprises viral infection with a lentiviral vector or a retrovirus.
10 . The method of claim 1 , wherein the one or more molecular characteristics of the pre-modified T-cell culture include T-cell activation, metabolism, exhaustion, and T-cell receptor diversity, and wherein the one or more molecular characteristics of the CAR T-cell culture during or after any one of steps (c)-(g) are selected from the group consisting of a gene expression, a protein expression, an mRNA expression, and a copy number variation.
11 . The method of claim 1 , wherein at least 500 gene expressions are determined.
12 . The method of claim 1 , wherein the optimizing further includes increasing or decreasing a temperature of the CAR T-cell culture.
13 . The method of claim 1 , wherein the ectodomain includes a signaling peptide, an antigen recognition region, and a spacer.
14 . The method of claim 13 , wherein the signaling peptide comprises a single-chain variable fragment (scFV).
15 . The method of claim 14 , wherein the single-chain variable fragment signaling peptide includes a light chain and a heavy chain of immunoglobins connected with a short linker peptide.
16 . The method of claim 1 , wherein the transmembrane domain is a hydrophobic α-helix that spans a membrane.
17 . The method of claim 1 , wherein the endodomain is a CD3-ζ endodomain, which includes 3 immunoreceptor tyrosine-based activation motifs (ITAMs).
18 . The method of claim 1 , wherein step (h) is performed with a sample input of CAR-T cells of the CAR-T cell culture, a CAR-T manufacturing product, or nucleic acids.
19 . The method of claim 1 , wherein step (a) is performed with a sample input of sorted T-cells of the pre-modified T-cell culture, whole blood, or nucleic acids.